Andrew Spaventa - Feb 12, 2025 Form 4 Insider Report for Singular Genomics Systems, Inc. (OMIC)

Signature
/s/ Dalen Meeter, Attorney-in-Fact
Stock symbol
OMIC
Transactions as of
Feb 12, 2025
Transactions value $
-$15,912
Form type
4
Date filed
2/14/2025, 05:00 PM
Previous filing
Dec 17, 2024
Next filing
Feb 25, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OMIC Common Stock Options Exercise +1.91K +586.77% 2.23K Feb 12, 2025 Direct F1
transaction OMIC Common Stock Sale -$15.9K -800 -35.84% $19.89 1.43K Feb 14, 2025 Direct F2, F3
transaction OMIC Common Stock Gift $0 -1.11K -77.3% $0.00 325 Feb 14, 2025 Direct F4
transaction OMIC Common Stock Gift $0 +1.11K +0.78% $0.00 143K Feb 14, 2025 By The Andrew K. Spaventa Living Trust dated April 9, 2014 F4
holding OMIC Common Stock 85 Feb 12, 2025 By Axon Holdings, LLC F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OMIC Restricted Stock Units Options Exercise $0 -1.91K -7.7% $0.00 22.9K Feb 12, 2025 Common Stock 1.91K Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of Common Stock issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The shares were sold pursuant to pre-established trading instructions solely to satisfy tax withholding obligations in connection with the partial vesting of previously granted RSUs.
F3 Represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $19.88 to $19.91, inclusive. For all transactions reported in this Form 4 utilizing a weighted-average price, the reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4 Immediately upon settlement of the vested RSUs, and following the withholding described above, the Reporting Person transferred the shares as a gift to The Andrew K. Spaventa Living Trust dated April 9, 2014.
F5 The shares are held directly by Axon Holdings, LLC. The managing member of Axon Holdings, LLC is Axon Managers, LLC. The Reporting Person is a managing member of Axon Managers, LLC and may be deemed to have shared voting and investment power over the shares held by Axon Holdings, LLC. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F6 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F7 The RSUs vest in 16 equal quarterly installments over four years measured from February 12, 2024.